Community Practice Connections : Oncology Best Practice : Choosing Therapies for Patients with EGFR-mutant Lung Cancers : More Options... More Decisions... Better Outcomes
WebcastFaculty
OVERVIEW
Community Practice Connections : Oncology Best Practice : Choosing Therapies for Patients with EGFR-mutant Lung Cancers : More Options... More Decisions... Better Outcomes is organized by Physicians Education Resource, LLC (PER) and will be held during Apr 27, 2017 - Apr 27, 2018.
The target audience for this medical event for oncologists who treat patients with lung cancers. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cancer are also invited to participate. This CME Conference has been approved with a maximum of 2.0 AMA PRA Category 1 Credits.
Conference Objectives :
• Detail evidence that underlies the application of optimized front-line strategies to manage EGFR-mutated advanced NSCLC.
• Describe methods to optimize EGFR subtyping and emerging technologies that can practically facilitate tumor testing, as well as overcome inherent challenges to optimized testing in community settings where advanced NSCLC is managed.
• Explain how to optimize the timing of clinical interventions in relapsed advanced NSCLC settings and the trial evidence that informs decision-making to treat patients with EGFR-TKI resistance.
• Address treatment-related toxicities and methods to optimize the management of central nervous system metastases in the care of patients with advanced NSCLC.
Additional details will be posted as soon as they are available.
The target audience for this medical event for oncologists who treat patients with lung cancers. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cancer are also invited to participate. This CME Conference has been approved with a maximum of 2.0 AMA PRA Category 1 Credits.
Conference Objectives :
• Detail evidence that underlies the application of optimized front-line strategies to manage EGFR-mutated advanced NSCLC.
• Describe methods to optimize EGFR subtyping and emerging technologies that can practically facilitate tumor testing, as well as overcome inherent challenges to optimized testing in community settings where advanced NSCLC is managed.
• Explain how to optimize the timing of clinical interventions in relapsed advanced NSCLC settings and the trial evidence that informs decision-making to treat patients with EGFR-TKI resistance.
• Address treatment-related toxicities and methods to optimize the management of central nervous system metastases in the care of patients with advanced NSCLC.
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links